SCHEMBL5082647

SCHEMBL5082647

CCOC(=O)c1cccc(N)c1Cl

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.70
HSD17B10 Q99714 5/20 0.70
TSHR P16473 1/20 0.59
CDC25B P30305 4/20 0.55
HTT P42858 1/20 0.48
MAPT P10636 3/20 0.48
HPGD P15428 2/20 0.48
ALOX15 P16050 2/20 0.48
RAB9A P51151 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
GAA P10253 1/20 0.48
KDM4E B2RXH2 3/20 0.48
POLB P06746 1/20 0.48
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
METTL3 Q86U44 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11655537 0.87 ALDH1A1 (0.62) ALDH1A1HSD17B10TSHRCDC25BHPGD
SCHEMBL3699729 0.83 TSHR (0.63) ALDH1A1HSD17B10TSHRCDC25BMAPT
SCHEMBL2925689 0.83 ALDH1A1 (0.74) ALDH1A1HSD17B10TSHRCDC25BMAPT
SCHEMBL11418791 0.83 TSHR (0.63) ALDH1A1HSD17B10TSHRCDC25BMAPT
SCHEMBL717606 0.83 ALDH1A1 (0.74) ALDH1A1HSD17B10TSHRCDC25BMAPT
Ethyl Anthranilate SCHEMBL34474 0.82 ALDH1A1 (1.00) ALDH1A1HSD17B10TSHRCDC25BMAPT
Ethyl Anthranilate SCHEMBL30055126 0.82 ALDH1A1 (1.00) ALDH1A1HSD17B10TSHRCDC25BMAPT
SCHEMBL27560434 0.81 CA12 (0.62) ALDH1A1HSD17B10TSHRCDC25BMAPT
SCHEMBL177310 0.81 ALDH1A1 (0.72) ALDH1A1HSD17B10TSHRCDC25BMAPT
SCHEMBL2894636 0.81 ALDH1A1 (0.72) ALDH1A1HSD17B10TSHRCDC25BMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119552089-A Preparation method of 3-amino-2-fluorobenzoyl chloride and derivatives thereof 帕潘纳(北京)科技有限公司 2025-03-04 CN disclosed
EP-2585454-A1 HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS Novartis AG (CH) 2013-05-01 EP disclosed
CN-103080107-A Heteroaryl compounds and compositions as protein kinase inhibitors NOVARTIS AG 2013-05-01 CN disclosed
US-20130096149-A1 HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2013-04-18 US disclosed
WO-2011161216-A1 HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2011-12-29 WO disclosed
US-20080177002-A1 Thermoplastic Resin Composition, Optical Film, And Process For Producing Film JSR CORPORATION (JP) 2008-07-24 US disclosed
CN-101098931-A Thermoplastic resin composition, optical film, and process for producing film JSR CORP (JP) 2008-01-02 CN disclosed
EP-1837374-A1 THERMOPLASTIC RESIN COMPOSITION, OPTICAL FILM, AND PROCESS FOR PRODUCING FILM JSR Corporation (JP) 2007-09-26 EP disclosed
US-4148805-A POLYESTERS, RED, YELLLOW CIBA-GEIGY AG (CH) 1979-04-10 US disclosed
US-4104049-A Chlorine-substituted vinylaminobenzoic acid compounds and plant growth regulant compositions BAYER AKTIENGESELLSCHAFT (DE) 1978-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096149-A1 HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS BRAF, RAF1, ARAF ALDH1A1 3123/4885HSD17B10 1872/4885TSHR 1740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.